Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8315932 | 0.93 | MEN1 (0.57) | GRM5MEN1KMT2ANPSR1LNPEP | |
| SCHEMBL22563072 | 0.90 | GRM5 (0.52) | GRM5MEN1KMT2ANPSR1LNPEP | |
| SCHEMBL15747743 | 0.90 | LNPEP (0.54) | GRM5MEN1KMT2ANPSR1LNPEP | |
| SCHEMBL21384574 | 0.88 | TDP1 (0.50) | GRM5MEN1KMT2ANPSR1LNPEP | |
| SCHEMBL3714668 | 0.87 | SMN1; SMN2 (0.44) | GRM5MEN1KMT2ANPSR1LNPEP | |
| SCHEMBL31131400 | 0.86 | LNPEP (0.49) | GRM5MEN1KMT2ANPSR1LNPEP | |
| SCHEMBL22551243 | 0.86 | LNPEP (0.49) | GRM5MEN1KMT2ANPSR1LNPEP | |
| SCHEMBL25929764 | 0.86 | LNPEP (0.49) | GRM5MEN1KMT2ANPSR1LNPEP | |
| SCHEMBL6395476 | 0.86 | NPC1 (0.53) | GRM5LNPEPSMN1; SMN2NPC1RAB9A | |
| SCHEMBL29995210 | 0.86 | MEN1 (0.54) | GRM5MEN1KMT2ANPSR1LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230035133-A1 | [1,2,4]Triazolo[4,3-B]Pyridazines For Use in the Treatment of Proliferative Diseases | ASTRAZENECA AB (SE) | 2023-02-02 | — | — | US | disclosed |
| US-20230035133-A1 | [1,2,4]Triazolo[4,3-B]Pyridazines For Use in the Treatment of Proliferative Diseases | ASTRAZENECA AB (SE) | 2023-02-02 | — | — | US | disclosed |
| US-11407755-B2 | [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2022-08-09 | — | — | US | disclosed |
| US-20210107905-A1 | 1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2021-04-15 | — | — | US | disclosed |
| US-20210107905-A1 | 1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2021-04-15 | — | — | US | disclosed |
| US-10766905-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2020-09-08 | — | — | US | disclosed |
| US-10766905-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2020-09-08 | — | — | US | disclosed |
| US-20200055861-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA UK LIMITED (GB) | 2020-02-20 | — | — | US | disclosed |
| US-20200055861-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA UK LIMITED (GB) | 2020-02-20 | — | — | US | disclosed |
| US-10407432-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2019-09-10 | — | — | US | disclosed |
| EP-2430024-A1 | [1,2,4]TRIAZOLO [4,3-B]PYRIDAZINES AS LIGANDS OF THE ANDROGEN RECEPTOR | AstraZeneca AB (SE) | 2012-03-21 | — | — | EP | disclosed |
| EP-2396333-A1 | TRIAZOLO [4,3-B]PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | AstraZeneca AB (SE) | 2011-12-21 | — | — | EP | disclosed |
| US-8003649-B2 | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155 | ASTRAZENECA AB (SE) | 2011-08-23 | — | — | US | disclosed |
| WO-2010131022-A1 | [1,2,4] TRIAZOLO [4,3-B] PYRIDAZINES AS LIGANDS OF THE ANDROGEN RECEPTOR | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292222-A1 | CHEMICAL COMPOUNDS 751 | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D | 2010-10-21 | — | — | US | disclosed |
| EP-2235010-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2010092371-A1 | TRIAZOLO [4,3-B] PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | WO | disclosed |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| WO-2009081197-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407432-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | MKI67, CCNB1, CCNB2 | GRM5 3828/4885MEN1 619/4885KMT2A 2735/4885 |
| US-20100292222-A1 | CHEMICAL COMPOUNDS 751 | AR, NR5A1, KLK3 | GRM5 442/4885MEN1 476/4885KMT2A 1270/4885 |
| US-20200055861-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | MKI67, CCNB1, CCNB2 | GRM5 3828/4885MEN1 619/4885KMT2A 2735/4885 |
| US-20210107905-A1 | 1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | MKI67, CCNB1, BCL2 | GRM5 3878/4885MEN1 794/4885KMT2A 2678/4885 |
| US-11407755-B2 | [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases | MKI67, CCNB1, CCNB2 | GRM5 3828/4885MEN1 619/4885KMT2A 2735/4885 |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | AR, KLK3, ESRRA | GRM5 1297/4885MEN1 618/4885KMT2A 1460/4885 |
| US-20230035133-A1 | [1,2,4]Triazolo[4,3-B]Pyridazines For Use in the Treatment of Proliferative Diseases | MKI67, CCNB1, CCNB2 | GRM5 3828/4885MEN1 619/4885KMT2A 2735/4885 |
| US-10766905-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | MKI67, CCNB1, CCNB2 | GRM5 3828/4885MEN1 619/4885KMT2A 2735/4885 |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | AR, NR5A1, CYP17A1 | GRM5 305/4885MEN1 1150/4885KMT2A 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.